Ongoing reviews are evaluating how maternal factors may contribute to premature births. Protocol teams are now amending the entry criteria to exclude women at high risk for premature delivery, and Dr. Mofenson expects the ACTG trials to reopen again within the next few weeks. In the meantime, NIH officials recommend that pregnant women on combination therapy for HIV infection continue their regimens as prescribed by their physicians. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.